HLA-B27 isn't a typical single gene in the way most spotlight genes are — it's a variant of a human leukocyte antigen (HLA) gene, part of the immune system's machinery for identifying and presenting foreign invaders to immune cells. Carrying the HLA-B27 variant is strongly associated with a group of inflammatory joint conditions collectively called spondyloarthropathies, the best known of which is ankylosing spondylitis (AS) — a chronic inflammatory disease primarily affecting the spine and sacroiliac joints, typically emerging in young adulthood.
A Strong Association That Still Isn't a Diagnosis
The numbers here are genuinely striking in both directions. Roughly 5-9% of the general Western population carries HLA-B27, yet up to 90% of people diagnosed with ankylosing spondylitis carry it — one of the strongest single-gene associations found for any common autoimmune condition, with the variant contributing to somewhere around 20-50% of the total estimated genetic risk for the disease. But flip the statistic around: since ankylosing spondylitis itself affects only roughly 0.1% to 1.4% of the general population, and HLA-B27 carriage is far more common than that, the clear majority of HLA-B27 carriers never develop ankylosing spondylitis at all. More than forty other genetic loci have also been identified as contributing to AS risk, meaning HLA-B27 is a major piece of the puzzle, not the whole picture.
| Population | HLA-B27 prevalence |
|---|---|
| General Western population | ~5-9% |
| Ankylosing spondylitis patients | ~80-90% |
| Psoriatic arthritis / inflammatory bowel disease patients | Under 50% |
HLA-B27 is also linked, to a lesser degree, with reactive arthritis (sometimes triggered by certain gut or urogenital infections) and acute anterior uveitis, an inflammatory eye condition — meta-analyses have found the incidence of uveitis among HLA-B27-positive individuals ranges widely depending on the population studied, and it can actually precede a formal AS diagnosis by several years, making it sometimes the first visible clue that something else is going on.
HLA-B27 is a strong risk marker, not a diagnosis. Most carriers never develop ankylosing spondylitis. Its real clinical value is in context — alongside symptoms like chronic lower back pain that improves with activity and worsens with rest, morning stiffness, or unexplained eye inflammation — where a positive result meaningfully speeds up an otherwise often-delayed diagnosis.
Why Diagnosis Speed Matters Here
Ankylosing spondylitis is notorious for diagnostic delay, often years, partly because early symptoms (back pain in young adults) get attributed to more common, less serious causes first. Knowing your HLA-B27 status in advance — particularly if you have a family history of AS or related spondyloarthropathies — gives your doctor a meaningful data point to weigh much earlier in that process, potentially shortening the path to correct diagnosis and treatment.
Autoimmune Risk Markers Are Part of Your Genome
Dante Labs' whole genome sequencing captures HLA-B27 and other immune-relevant variants alongside carrier and ancestry results. Use code GENOME for 10% off.
Get Sequenced with Dante Labs → 10% off with code GENOMEFor more on how genetic markers inform, rather than replace, clinical diagnosis, see our explainer on variants of uncertain significance and our broader guide to genome testing and disease risk.